Zepp Health ADR A

Zepp Health reported a 6.9% revenue increase to $63.5 million in Q2 2026 and an improved gross margin of 37.4%, while adjusted operating loss widened to $11.1 million. Higher sales and marketing expenses for several product launches as well as increased component and storage costs weighed on results. The company holds $106.3 million in liquidity, has reduced debt and expects Q3 revenue of $68–73 million; supply shortages are expected to gradually normalize. Management sees a strategic shift toward premium products and plans fewer product launches in the second half of the year to ease cost pressure. » Więcej na de.investing.com

Zepp Health reported revenue of $51.5 million in Q1 2026, up 33.8% year over year, supported by several new wearable products. Gross margin rose to 37.7%, operating loss improved to $6.3 million, and adjusted net loss narrowed slightly to $17.9 million. The stock rose 3.55% in after-hours trading. Management expects EPS of $0.10 for FY2026 and $1.16 for FY2027, and revenue forecasts of $334 million (FY2026) and $392.78 million (FY2027), but sees risks from higher operating costs and supply chain constraints. » Więcej na de.investing.com

Zepp Health's shares have gained almost 1,100% over the past six months after the company reported accelerating sales driven by strong demand for Amazfit wearables and better-than-expected quarterly revenue. Management projected continued top-line growth and Q3 revenue came in at $75.8 million, up 78.5% year over year, while the company is moving toward profitability. Despite the rally, Zepp remains below its 2018 IPO debut and still posts losses, presenting valuation and execution risks for investors. » Więcej na finance.yahoo.com